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Rhabdomyosarcoma (RMS) is the most common soft tissue malignancy in childhood and adolescence. The two major histological
subtypes of RMS are alveolar RMS, driven by the fusion protein PAX3-FKHR or PAX7-FKHR, and embryonic RMS, which is
usually genetically heterogeneous. The prognosis of RMS has improved in the past several decades due to multidisciplinary care.
However, in recent years, the treatment of patients with metastatic or refractory RMS has reached a plateau. Thus, to improve the
survival rate of RMS patients and their overall well-being, further understanding of the molecular and cellular biology of RMS and
identification of novel therapeutic targets are imperative. In this review, we describe the most recent discoveries in the molecular
and cellular biology of RMS, including alterations in oncogenic pathways, miRNA (miR), in vivomodels, stem cells, and important
signal transduction cascades implicated in the development and progression of RMS. Furthermore, we discuss novel potential
targeted therapies that may improve the current treatment of RMS.
1. Introduction
Rhabdomyosarcoma (RMS) is the most prevalent soft tissue
tumor in children and adolescents, accounting for 5% of all
pediatric tumors [1, 2]. It is estimated that 350 new cases of
RMS are diagnosed each year in patients under 20 years of
age in the United States [2]. In contrast, RMS is extremely
rare in adults. There is a slight male predominance (1.4 times
more common in males than in females), but there are no
significant differences in the incidence rates among races or
different ethnic groups [3]. As RMS is derived from primitive
mesenchymal stem cells directed towards myogenesis, it can
arise in a variety of anatomic sites throughout the body [4].
RMS can occur either as a primary malignancy or as a com-
ponent of a heterogeneous malignancy, such as a malignant
teratomatous tumor [5]. Additionally, a small percentage of
cases are associated with known genetic disorders, such as
neurofibromatosis type 1 and the Li-Fraumeni familial cancer
syndrome [6].
The World Health Organization (WHO) recently revised
the classification of RMS subtypes as alveolar rhabdomyo-
sarcoma (ARMS), embryonal rhabdomyosarcoma (ERMS),
pleomorphic rhabdomyosarcoma (PRMS), and sclerosing/
spindle cell rhabdomyosarcoma (SRMS) in 2013 [7]. ARMS is
a high-grademalignancy occurringmostly in adolescents and
young adults.Themost common site for ARMS is in the deep
tissue of extremities. ERMS represents approximately 70%
of all childhood RMS, usually afflicting infants or children
under 10 years of age. ERMS often affects the head and neck
regions, especially the orbit. PRMS usually occurs in adult
males in the deep tissue of extremities but may occur at any
site. In adult patients, the pleomorphic variant is associated
with the worst prognosis [8].
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Table 1: Alterations of chromosome in RMS by CGH in recent 5 years.
Materials Gain Amplification Loss Deletion Reference
25 RMS samples 2p, 12q, 6p, 9q, 10q, 1p,2q, 6q, 8q, 15q, 18q 3p, 11p, 6p Li et al., 2009 [16]
13 RMS cell lines
1p21.3–13.2, 1q12,
6q26–27, 7q21.3–31.1,
1q41, 2p24.3, 8q24.12,
20q13.2, 20q13.32
2p24.3 (MYCN),
8p11.23–11.21
(FGFR1), 12q13.3
(CDK4), 19q12, 20q
3p14.2–12.2,
4q27–32.3,
6p25.1–24.3,
9p24.3–24.1, 13q14.3
Missiaglia et al., 2009
[17]
57 ARMS
samples 12q15, 2p24, 12q13–q14 Barr et al., 2009 [18]
128 primary
RMS samples 7, 8, 11, 20
2p24.1 (MYCN),
8p11.2–p11.1 (FGFR1),
12q13.3–14.1 (CDK4),
MDM2 (12q14.3–q15)
Williamson et al.,
2010 [12]
26 frozen
primary ERMS
samples
8, 2, 11, 12, 13, 19, 20
2p21, 2q35, 2q14.2,
2q36.1, 5q35.2–q35.3,
11p11.2, 11q24.2,
12q13.3
6, 9, 10, 14, 15, 16, 18
1p36.23, 1q32.1, 3p14.2,
4q35.1–35.2, 9p21.3,
17q11.2, 22q13.31
Paulson et al., 2011
[13]
39 RMS samples 12q13.3, 12q13.3–q14.1,12q14.1, 17q25.1
2q13.12, 12q13.3,
12q13.3–q14.1
9p12–p11.2,
10q11.21–q11.22,
14q32.33, 16p11.2,
22q11.1
1p21.1, 2q14.1, 5q13.2,
9p12, 9q12 Liu et al., 2014 [11, 15]
RMS cells
derived from
refractory RMS
NACA, HSD17B6,
SDR9C7, RDH16,
GPR182, ZBTB39,
TAC3, MYO1A,
NAB2, STAT6, LRP1
Park et al., 2014 [14]
20 RMS samples
of Chinese
patients
12q24.31, 17q25.1,
1q21.1, 7q11.23,
12q13.3–q14.1
9p13.3, 12q13.3–q14.1,
12q15, 16p13.11
5q13.2, 15q11.2,
14q32.33 (IGHG,
IGHM)
1p36.33, 1p13.1, 2q11.1,
5q13.2, 8p23.1, 9p24.3,
16p11.2
Liu et al., 2014 [11, 15]
Since the 1970s, the Intergroup Rhabdomyosarcoma
Study Group (IRSG) has conducted a series of clinical trials
comparing risk-base and has established a series of treatment
guidelines [9]. Currently, multidisciplinary management
including chemotherapy and surgery with or without radia-
tion has become the standard treatment for RMS. The 5-year
survival rate of RMS has increased from 25% in 1970 up to
60% since 2000 [1, 10].However, there has been little improve-
ment in the oncological outcome of patients with RMS in
recent years. Drug resistance andmetastatic disease represent
the two most common phenomena for therapy failure. Some
randomized chemotherapy trials have failed to improve out-
come despite the introduction of newer or more intensive
therapies. Thus, there is an urgent need for alternative, more
effective treatment strategies. Recent molecular and genetic
analysis of these tumors has produced substantial new
insights into molecular cell biology, molecular cytogenetics,
and tumorigenesis of RMS, leading to a better understanding
of RMS development at the molecular level. These advances
may ultimately lead to better clinical understanding and to
potentially developing more potent targeted therapies. The
purpose of this review is to summarize these most recent
findings in RMS.
2. Novel Discoveries of Chromosomal
Alterations in RMS
Malignant transformation occurs cytogenetically due to the
accumulation of somatic mutations by the acquisition of
tumor-specific chromosomal translocations.
2.1. Gains and Losses of Chromosomes in RMS. Comparative
Genomic Hybridization (CGH) analysis has revealed that all
RMS have specific gains and losses [11–18] (Table 1). ERMS
frequently exhibits gains or losses of specific whole chromo-
somes, whereas ARMS is characterized by the presence of
regions of genomic amplification [11, 19]. The focal regions
and genes, most of which have frequent gains and ampli-
fications, include 12q13.3–q14.1 and 8p11.2–11.2 and CDK4,
MYCN, GLI, MDM2, FGFR1, and FGFR4, respectively. Fre-
quently, the genes differentially expressed in subtypes of
RMS, particularly when they are from chromosomal regions,
show a high level of gains in cell lines. Previous CGH studies
have shown that ARMS tumors tend to have fewer copy
number variants than ERMS tumors [12, 20]. For example,
frequent gains were detected in TYROBP, HCST, LRFN3,
and ALKBH6 (19q13.12) in ERMS, but not in ARMS [15].
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Figure 1:The chromosomal rearrangements in ARMS. 80% of ARMS classified as translocation-positive ARMS carry characteristic chromo-
somal translocations demonstrated as t(2;13)(q35;q14), t(1;13)(p36;q14), and (2;2)(q35;p23). In (a) and (b), the translocations fuse the FKHR
(a member of the forkhead/HNF-3 transcription factor family) locus on chromosome 13 to either PAX3 on chromosome 2 or PAX7 on
chromosome 1. In (c), the translocation generated a fusion protein composed of PAX3 and the nuclear receptor coactivator NCOA1, having
similar transactivation properties as PAX3/FKHR.
These studies have identified a number of genetic alterations
in RMS.Many of these chromosomal changesmay be respon-
sible for tumor progression and proliferation. These genetic
alterations may be potential treatment targets in RMS [11].
2.2. Chromosomal Translocations in ARMS. Chromosomal
analyses have demonstrated two translocations associated
with ARMS, t(2;13)(q35;q14) and t(1;13)(p36;q14) [21]. Initial
studies detected these two gene fusions in 80% of ARMS
[22]. These characteristic chromosomal translocations are
adjacent to the 5󸀠 DNA-binding domains of PAX, a member
of the paired box transcription factor family, and the trans-
activation domain at the 3󸀠 end of FKHR, a member of the
forkhead/HNF-3 transcription factor family. Approximately
75% of these structural rearrangements translocate the PAX3
gene at 2q35 to the FKHR gene at 13q14, as t(2;13)(q35;q14);
less frequently, in the other 25%, the t(1;3)(q36;q14) transloca-
tion fuses PAX7 to FKHR [23]. Previous studies have demon-
strated that PAX3/FKHR fusion gene status significantly
improves current risk stratification, while the presence of
PAX7/FKHR and rarer variant fusion gene products require
further investigation [24]. The remaining 20% of ARMS is
PAX gene fusion-negative (PFN) and forms a more hetero-
geneous group, which remains a challenge to detect due to
the lack of consistent chromosomal rearrangements. PFN
ARMS has a similar clinical course to ERMS, which suggests
that the fusion gene status provides more accurate informa-
tion about patient outcomes than did the histologic subtype.
Despite the low overall burden of somatic mutations in
fusion-positive RMS,multiple genes were recurrently altered,
including NRAS, KRAS, HRAS, FGFR4, PIK3CA, CTNNB1,
FBXW7, and BCOR [25].
Another novel translocation, t(2;2)(q35;p23), was identi-
fied in ARMS biopsy samples by gene expression signatures
[26]. The chromosomal translocation generates a fusion pro-
tein composed of PAX3 and the nuclear receptor coacti-
vator NCOA1, which has similar transactivation properties
as PAX3/FKHR [26]. These biologic effects contribute to
tumorigenesis bymodulatingmyogenic differentiation, alter-
ing growth and apoptotic pathways, and stimulating motility
and other metastatic pathways (Figure 1).
2.3. Chromosomal Alterations in ERMS. ERMS exhibits a loss
of imprinting (LOI), leading to a twofold gene dosage effect
[27]. Most tumors have at least one 15-Mb region with loss of
heterozygosity (LOH) along chromosome 11 [27]. The allelo-
type of ERMS demonstrates a high frequency of LOH on
chromosomes 11p, 11q, and 16q [28]. ERMS tumorigenesis
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Table 2: The histological types of rhabdomyosarcoma.
Histological type Predilection population Predilection site Risk category Genetic change
ERMS Infants or children under 10years old Head and neck region Intermediate LOH at chromosome 11p15.5
ARMS Adolescents and young adults Deep tissue of extremity High t(2;13)(q35;q14); t(1;13)(p36;q14)
PRMS Adult males Throughout the body High
JUN (1p31), MYC (8q24),
CCND1 (11q13), INT2 (11q13.3),
MDM2 (12q14.3–q15)
SRMS
In the first decade of life with a
second mode centered around
the fifth decade
The extremities, head,
and neck Superior SRF-NCOA2; MYOD1 mutation
ERMS: embryonal rhabdomyosarcoma.
ARMS: alveolar rhabdomyosarcoma.
PRMS: pleomorphic rhabdomyosarcoma.
SRMS: spindle cell/sclerosing rhabdomyosarcoma.
can result from the inactivation of the parental bias of chro-
mosome 11p15, which is the most common rearrangement
in ERMS [29]. The proportion of ERMS with LOH along
chromosome 11 is considerably higher than in other subtypes
[27]. In histopathological analysis, ERMS expresses lowPAX3
levels and elevated PAX7 levels [30]. Hosoi et al. identified a
hidden 2q35 breakpoint as a novel PAX3 rearrangement in
complex chromosomal translocations in ERMS [31].
2.4. Chromosomal Alterations in Other RMS. There are lim-
ited studies on the biological pathways involved in other
subtypes of RMS, compared with the two major subtypes
ARMS andERMS. Fluorescence In SituHybridization (FISH)
reveals amplification of JUN (1p31), MYC (8q24), CCND1
(11q13), INT2 (11q13.3), MDM2 (12q14.3–q15), and MALT
(18q21) in these tumor cells, contributing to the pathogenesis
of PRMS [32]. MYOD1 homozygous mutations are also
reported as frequent, recurrent, and pathognomonic events
in adult-type SRMS [33, 34] (Table 2). Furthermore, four out
of five pediatric tumors showedMYOD1mutations in a study
[34]. Yoshida et al. described a 8q13 locus (NCOA2) gene
rearrangement in a small subset of SRMS occurring uniquely
in the infantile/congenital setting, fused with key transcrip-
tion factors involved in skeletal muscle differentiation, such
as SRF and TEAD1 [35]. They also identified NCOA2 as a
candidate PAX3 partner gene.ThePAX3-NCOA2 fusion gene
plays a dual role in the tumorigenesis of RMS, promotion of
the proliferation, and inhibition of the myogenic differenti-
ation of RMS cells [35]. As PAX3-NCOA2-induced tumors
grow more slowly, SRMS that are PAX3-NCOA2 fusion-
positive could be associated with a very favorable prognosis
[36].
Not all RMSs occur as sporadic primary tumors. Occa-
sionally, RMS inherits a mutant gene as part of an established
familial syndrome. For example, Beckwith-Wiedemann Syn-
drome (BWS) with RMS involves dysregulation or alteration
of imprinted genes in the 11p15.5 chromosomal region,
including IGF2, H19, and CDKN1C (p57/KIP2) [37].
3. Cell of Origin in RMS
There have been a number of studies aimed at deciphering the
cell origin for RMS [56–61].
3.1. Myogenic Differentiation in the Tumorigenesis. Several
studies have focused on elucidating the mechanisms govern-
ing the impaired myogenic program in RMS [62, 63] (Fig-
ure 2). RMSoriginates as a consequence of regulatory disrup-
tion of the growth and differentiation of myogenic precursor
cells. Progenitor cells reside in muscle and their activation
results in either proper myogenesis or aberrant signaling
pathways leading to the development of RMS. Based on the
skeletal muscle lineage, a complete transcriptome analysis of
RMS was performed to compare normal and fetal muscles
[56]. The high degree of similarity between fetal muscle and
RMS expression profiles reflects the undifferentiated myo-
genic nature of RMS. The genes exclusively upregulated in
RMS, including FGFR4, NOTCH2, UBE2C, UHRF1, and
YWHAB genes, contribute to the failure of RMS cells to com-
plete normal skeletal muscle development and progress to
an alternative fate [56]. RMS cells represent an arrested state
in the development of normal skeletal muscle, with regional
silencing of differentiation factors leading to the maturation
defect in RMS [57]. The expression pattern of muscle-
specific proteins regulating myogenic differentiation has
been extensively examined in RMS. The family of myogenic
transcription factors (MYOD, MYF5, myogenin, and MRF4)
are considered to be responsible for the determination of stem
cells intomyoblasts anddifferentiation intomyocytes [58, 59].
All these factors are activated during the onset or progression
of myogenesis and are subsequently silenced to reach a final
muscular differentiation. There are statistical differences in
the different subtypes of RMS tumors with MYOD or myo-
genin staining patterns. Amplification of MDM2 in an RMS
cell line interferes with MYOD activity and consequently
inhibits overt muscle cell differentiation [61]. Interleukin-4
receptor (IL-4R) has also been proposed to be important for
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Table 3: Studies identifying stem cells in RMS.
Marker/substrate Source Stem cell gene Functional characterization Reference
CD133 Orthotopicxenograft model
OCT4, NANOG, c-MYC,
PAX3, and SOX2
Correlating with poor overall
survival
Walter et al.,
2011 [38]
PAX-FKHR Bone marrow ofC57BL/6 mice
Myf5, MEF2, MyoD, and
myogenin
Determining the molecular,
myogenic, and histologic
phenotype of ARMS
Ren et al., 2008
[39]
V-ATPase RD cell line NANOG and OCT3/4
Driving mechanisms of a
reduced sensitivity to anticancer
drugs and activities related to
invasion and metastasis
Salerno et al.,
2014 [40]
Surv.m-CRAs
KYM-1 cell line
(FGFR3-
positive)
FGFR3
Therapeutic effectiveness against
all cell populations and increased
effectiveness against CSCs
Tanoue et al.,
2014 [41]
Migration
specification
Injured 
muscle
Terminal 
differentiation 
Fusion
PAX7
Myoblasts
Myoblast
MyoD
MyoD
Myf5
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Rb
Ezh2
IGF2
HDAC4YY1
YY1
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AKT
RMS
Myogenin
P38 kinase
Myostatin
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cell
N-RAS
Myofibers
FGFR4
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YWHAB
Satellite cells
RUNX1, MEF2C,
JDP2, NFIC
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n
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Earlydifferentiation
TGF-𝛽1
Figure 2: Myogenic pathways in the tumorigenesis of RMS. In aberrant neoplastic condition, progenitor cells residing in muscle result in
aberrant pathways, which lead to malignant transformation and fail to differentiate, proliferate uncontrollably, and form RMS. Sharp arrows
(→) indicate upregulation/activation and blunt arrows (⊥) indicate downregulation/inhibition.
the maturation of myotubes [64]. An IL-4R blockade might
help therapeutically to modulate the expression of myogenic
transcription factors (MYOD or myogenin) [57, 64].
3.2. Potential Cancer Stem Cell in RMS. Cancer Stem Cells
(CSCs) may contribute to inherent refractory responses to
current therapies andmetastasis [65].Many CSCmodels play
an important role in the development of RMS [38–41, 66]
(Table 3).
A study explored a potential important role for mesen-
chymal stem cells (MSCs) as the cell of origin of ARMS [67].
Ren et al. confirmed that PAX-FKHR fusion genes commit
MSCs to a myogenic lineage by inhibiting terminal differen-
tiation and contributing to ARMS formation [39]. Another
study showed that PAX-FKHR induces skeletal myogenesis
in MSCs by transactivating MYOD and myogenin and trans-
forms mesenchymal progenitor cells to the skeletal muscle lin-
eage leading to malignant formation resembling ARMS [39].
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Figure 3: Genetic analyses of RMS have pinpointed several common alterations, including inactivation of a master regulator of p53 and
Rb pathways, CDKN2A/B, and activation of FGFR4, RAS, and Hedgehog (Hh) signaling. The modifications of these pathways influence
oncogenesis and metastatic potential.
As a human hematopoietic CSC marker, Walter et al.
proposed that upregulated CD133 in ERMS can act as a
prognostic marker and might help with the development of
novel targeted therapies for ERMS [38].
4. Signaling Pathway Alterations in RMS
Recent studies have looked into signaling pathway alterations
and their downstream effects in RMS.These new findings not
only helped to improve the understanding of this malignancy
but also offered novel potential therapeutic strategies for
improved treatment for patientswithRMS [68, 69] (Figure 3).
4.1. RAS Signaling Pathway. RASmutations commonlymain-
tain the protein in its GTP bound state and therefore render
it constitutively active in RMS. Zhang et al. identified RAS
family members NRAS, KRAS, and HRAS in the RAS
pathway as themost commonlymutated genes in ERMS [70];
the mutation status of these genes is significantly associated
with the risk of ERMS development [70]. A study found
that a majority of ERMS demonstrated activation of the RAS
pathway exclusively either by homozygous deletion of NF1
or by point mutations in one of the RAS family members as
described above [13]. Despite remarkable genetic and molec-
ular heterogeneity, most (93%, 41/44) RMS tumors hijacked
a common receptor tyrosine kinase/RAS/PIK3CA genetic
axis [25]. It could occur via two alternative mechanisms:
rearrangement of a PAX gene and accumulation of mutations
that were downstream targets of the PAX fusion protein.
Skeletal muscle cells have a robust antioxidant defense
system to protect the DNA, lipids, and proteins from the
deleterious effects of excess Reactive Oxygen Species (ROS).
Cancer cells also have elevated ROS due to their increased
metabolic activity, oncogenic stimulation, andmitochondrial
dysfunction. These findings implicate RAS mutations and
oxidative stress as potential therapeutic targets for high-risk
ERMS.
4.2. IGF Signaling Pathway. There is clear preclinical data
that supports the involvement of the Insulin-like Growth
Factor (IGF) signaling pathway in RMS tumorigenesis and
progression [69]. Zhu and Davie demonstrated that IGF
promotes the proliferation of RMS cells, while blocking IGF
signaling interferes with cell growth in vivo.The IGF receptor,
IGF-1R, is highly overexpressed both on the cell surface and
in the nucleus of RMS cells; furthermore, RMS cell lines are
sensitive to IGF-1R inhibition.The IGF-2 locus shows a loss of
imprinting in both ERMS andARMS tumors, and the expres-
sion of PAX3-FKHR has been demonstrated to upregulate
IGF-2 and activate IGF pathway in ARMS [69]. Marianna
et al. found that IGF-2 and tumor suppressors p19Arf and
p21Cip1 are overexpressed and prominently upregulated in
RMS mouse models [71].
4.3. TGF-𝛽 Signaling Pathway. The regulatory role of Trans-
forming Growth Factor-𝛽 (TGF-𝛽) in RMS has been recently
studied [72]. Wang et al. demonstrated that the expression of
TGF-𝛽1 is significantly higher in RMS than in normal skeletal
muscle. The inhibition of TGF-𝛽1 expression by shRNA-
expressing vectors reverses themalignant behavior of RMSby
inhibiting cell growth and inducingmyogenic differentiation.
TGF-𝛽1 shRNA induces myogenin expression, a regulator of
myogenic differentiation genes. Myogenin acts as a target for
negative regulation of myogenesis by TGF-𝛽1 signals with
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a differentiation regulatory cascade. These results suggest
that the TGF-𝛽1 signaling pathway disrupts the differentia-
tion of myogenic progenitors, leading to the development of
RMS.
4.4. FGF Signaling Pathway. Fibroblast Growth Factor (FGF)
is crucial in embryonic development and functions to drive
proliferation. FGFs and their receptors (FGFRs) are essential
regulators in the processes of proliferation, antiapoptosis,
drug resistance, and angiogenesis in RMS [69]. RMS over-
expresses the receptor tyrosine kinase FGFR4, which causes
autophosphorylation and constitutive signaling in correlation
with poor differentiation and decreased survival [73]. Recent
work has shown that FGF signaling can prevent ARMS cells
from apoptosis induced by targeting the IGF1-R-PI3K-mTOR
pathway [74].
4.5. ERK Signaling Pathway. Previous studies have shown
that elevated myostatin expression deregulates Extracellular
Regulated Kinase (ERK) signaling and deficient activation
of the p38 pathway contributes to the differentiation block
in RMS cells [62]. The ERK pathway is frequently highly
activated in RMS cells from embryonic derivation due to the
presence of activating RASmutations, leading to reduced dif-
ferentiation by blocking the p38 pathway [75].These findings
indicate that interventions that target themyostatin/ERK/p38
network could be an effective way to promote differentiation
of RMS.
4.6. Hippo Signaling Pathway. Many upstream signal trans-
duction proteins, in response to cues from the cellular micro-
environment, regulate the core Hippo pathway [76]. The
Hippo pathway may limit tumorigenesis by inducing the
cytosolic localization of the transcriptional cofactor Yes-
Associated Protein 1 (YAP1). High YAP levels and activities
increase activated satellite cells and prevent differentiation
by activating genes that inhibit differentiation [77]. YAP1-
TEAD1 was found to upregulate proproliferative and onco-
genic genes and maintain the ERMS differentiation block
by interfering with MYOD1 and MEF2 prodifferentiation
activities [76]. Inhibition of theHippo pathway is exhibited in
RMS through downregulation of Hippo pathway tumor sup-
pressors or upregulation of YAP [78]. These data suggest that
Hippo pathway dysfunction promotes RMS development.
4.7. Notch Signaling Pathway and Wnt Signaling Pathway.
Notch pathway, as an embryonic signaling pathway, promotes
muscle stem cell maintenance by inhibiting myogenic early
differentiation and expanding pools of progenitor cells dur-
ing both embryogenesis and postnatal muscle regeneration.
Similar to Notch, Wnt has various roles in embryonic, fetal,
and neonatalmyogenesis during skeletalmyogenesis. As both
pathways are regulators of myogenic lineage determination
and maturation, RMS can arise from disordered regulation
of these normal developmental pathways [79].
4.8. Caveolins in RMS. Recent findings have shown that cav-
eolins are expressed in a cell stage-dependent manner in
RMS [80, 81]. Caveolins are scaffolding proteins that regulate
several targets and pathways (such as p53, IGF, RAS/ERK, and
TGF-𝛽/myostatin signaling) associated with RMS develop-
ment, and therefore loss or gain of caveolin function is able
to generate multiple effects on the tumor behavior.Therefore,
recognizing their precise roles in RMS progression will be
crucial to elaborate targeted therapies; particularly, as one
of the three different isoforms, CAV1, could act as a potent
tumor suppressor in ARMS. Inhibition of CAV1 function can
contribute to aberrant cell proliferation, leading to ARMS
development [80].
4.9. DNA Repairing System. Some studies indicate that RMS
is characterized by germline mutations of DNA repair genes
[82, 83]. DNA repair gene alterations in RMS occur sec-
ondarily to malignant transformation. The modifications
in DNA repair enzyme activity can result in resistance to
adjuvant treatment in RMS tumor cells, which limits the
prognosis of RMS. There are two pathways for repairing
DNA breaks: directly without affecting DNA structure and
indirectly by DNA phosphodiester backbone cleavage [82]
(Figure 4). Direct repair includes repair during replication
and enzymatic repair. Indirect repair is comprised of exci-
sion repair systems, including base excision repair (BER),
nucleotide excision repair (NER), mismatch repair (MMR),
and recombination repair (RR) [83]. Defective DNA repair
mechanisms result from point mutations or LOH in RMS
and contribute to tumorigenesis. MGMT and MMR protein
activity and expression levels are used as predictor indices for
therapy outcome in RMS. BER, as the major DNA repair sys-
tem against damage resulting from cellular metabolism, can
reverse the cytotoxic effects of alkylation agents used, such
as antineoplastics; subsequent tumor progression and death
implicates an RMS mechanism of resistance to chemother-
apeutic agents. This may provide novel individualized ther-
apeutics targeting downregulation of activated DNA repair
enzymes or upregulation of DNA repair deficiencies [82].
5. MicroRNA (miRNA, miR)
Expression in RMS
Muscle-specific and ubiquitously expressed miRs appear
downregulated in RMS tumors and cell lines compared with
the normal counterparts. These miRs often play crucial roles
as antioncogenes. Inhibition of these miRs contributes to
enhanced tumorigenesis through the modulation of diverse
molecular pathways. Upregulation of prooncogenic miRs has
been detected in RMS recently as well [84] (Table 4).
5.1. Antioncogenic miR in RMS. Gain-of-function experiments
have demonstrated that reexpression of selected “tumor sup-
pressor” miRs impairs the tumorigenic behavior of RMS cells
[84, 85]. As myo-miR family members, miR-1, miR-133a, and
miR-206 have been demonstrated to be downregulated in
RMS and shown to have activity on mRNA expression by
targeting c-Met [42, 43, 86]. Inhibition of thesemyo-miRNAs
may cause aberrant cell proliferation and migration in myo-
genesis, leading to RMS development, especially for ERMS.
There have been more miRs found as tumor suppressors in
this malignancy, including miR-29, miR-450b-5p, miR-203,
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Table 4: MicroRNAs involved in myogenesis and RMS development.
miRNA Expression Target Function Reference
miR-1 and miR-133a Downregulation MYH9
Myogenic miRNA, inhibit differentiation
and promote proliferation in myogenesis,
cytostatic
Rao et al., 2010 [42]
miR-206 Downregulation cMET Promote differentiation and proliferation
in myogenesis
Yan et al., 2009 [43]
miR-29 Downregulation HADC4, YY1, EZH2 Promote stabilization of RMS phenotype Marchesi et al., 2014 [44]
miR-450-5p Downregulation ENOX, PAX9 Promote differentiation and progression Sun et al., 2014 [45]
miR-203 Downregulation JAK, STAT, Notch Inhibit differentiation and proliferation in
myogenesis, tumor suppressor
Diao et al., 2014 [46]
miR-214 Downregulation N-Ras Inhibit tumor cell growth and induce
myogenic differentiation and apoptosis
Huang et al., 2014 [47]
miR-183 Upregulation EGR1 Promote migration and metastasis Sarver et al., 2010 [48]
PMS2
MGMT
HR
Mismatch Recombination
NHEJ MMEJ
p53
Excision
BER NER
RMS
DNA repair
Direct repair Indirect repair
repair repairrepair
Figure 4:The DNA repair systems in RMS.There are two pathways repairing the DNA lesions, directly without affecting DNA structure and
indirectly by DNA phosphodiester backbone cleavage. The modifications in DNA repair enzymes expression or activity lead to resistance
to chemotherapy and radiation in RMS tumor cells. MGMT, O6-methylguanine-DNA methyltransferase; BER, base excision repair; NER,
nucleotide excision repair; HR, homologous recombination; NHEJ, nonhomologous end-joining; MMEJ, microhomology-mediated end-
joining.
and miR-214 [44, 46, 47, 84, 87]. They are all significantly
downregulated in RMS compared with normal skeletal mus-
cles and function to inhibit tumor cell growth and induce
myogenic differentiation and apoptosis in RMS.
5.2. Oncogenic miRNA in RMS. The transcription factor EGR1
is a tumor suppressor gene that is downregulated in RMS [48].
miR-183 functions as an oncogene by targeting EGR1 and pro-
moting tumor cell migration. Either by direct anti-miR treat-
ment or by indirect mechanisms that decrease transcript,
miR-183 targeted treatmentsmight provide a potential option
to RMS patients.
The basic strategy of current effective miR-based treat-
ment studies is either efficient reexpression of miRs or restor-
ing the function of miRs to inhibit the expression of certain
protein-coding genes and promote muscle differentiation.
Moreover, miR expression profiling in tumors and, possibly,
their detection in peripheral blood during treatment may be
able to predict the response to chemotherapy or radiotherapy
and be useful as a prognostic signature for the development of
treatment resistance.The prognostic value of miR expression
levels in RMS is a powerful tool in creating a better-tailored
strategy for particular subsets of patients.
5.3. Long Noncoding RNAs in RMS. Long noncoding RNAs
(LNCRNAs) are abundant in the mammalian transcriptome
and have been shown to play a role in RMS development [88,
89].TheH19 gene, localized within a chromosomal region on
human chromosome 11p15, encodes an imprinted untrans-
lated RNA [90]. H19 opposite tumor suppressor (HOTS),
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Table 5: In vivo animal models of RMS.
Model Target Model origin Reference
Inactivation Expression
Drosophila
PAX-FKHR Bipartite Gal4-UASexpression system
Galindo et al.,
2006 [49]
PAX7-FOXO1 rols Chromosomal deletion,Df(3L)vin5
Avirneni-
Vadlamudi et al.,
2012 [50]
Zebrafish
rag2 promoter c-Myc kRASG12D
Chen and
Langenau, 2011
[51]
MAPK/ERK and
AKT/S6K1 PD98059, TPCK Tg(hsp70-HRAS
G12V) Le et al., 2012[52]
Mouse
Sufu N-myc, Sfrp1, Ptch2,and cyclin D1 Sufu
+/− Lee et al., 2007
[53]
Ink4a/Arf and Trp53 Pax3:FKHR Pax3P3Fp/wt Keller et al.,2004 [54]
Wnt/𝛽-catenin
signaling pathway Wnt2 p53
−/−/c-fos−/− Singh et al., 2010[55]
a tumor growth inhibitor, is encoded by an imprinted H19
antisense transcript. Overexpression of HOTS inhibits RMS
tumor cell growth. Silencing HOTS by RNAi was shown to
increase in vitro colony formation, as well as in vivo tumor
growth of RMS [90].
6. In VivoModels of RMS
Several in vivo models have recently been developed in
Drosophila, zebrafish, and mice to further understand the
molecular and cellular biology of RMS tumorigenesis [49–
55, 91–94] (Table 5).
6.1. Drosophila Models in RMS. Despite the evolutionary
distance, a strong conservation of genes, pathways, and
regulatory molecular networks have been demonstrated
between flies and humans. Many human disease genes have
related sequences in Drosophila. In contrast to mammalian
models, the generation of Drosophila mutants is easy, cheap,
and fast.
For a better understanding of the pathogenic conse-
quences of PAX-FKHR expression, Drosophila was chosen
because the animal’s transparent outer cuticle allows for
simple real-time monitoring of muscle abnormalities elicited
by PAX-FKHR, including subtle or focal changes [49]. The
mutation in the myoblast fusion gene rolling pebbles (rols)
was reported to dominantly suppress PAX-FKHR1-induced
lethality by using a Drosophila model of PAX-FKHR1-
mediated transformation [50]. PAX-FKHR1 signaling upreg-
ulates the TANC1 gene and blocks myoblasts from terminal
differentiation. However, downregulating the TANC1 gene
could cause RMS cells to lose their neoplastic state, undergo
fusion, and form differentiation. This novel finding uncov-
ered a PAX-FKHR1-TANC1 neoplasia axis collaboratively in
a Drosophila model and loss-/gain-of-function studies in
mammalian platforms [50].
6.2. Zebrafish Models in RMS. In contrast to other mod-
els, the short tumor onset in zebrafish allows for rapid
identification of essential genes in various processes, such
as tumor growth, self-renewal, and maintenance. There are
other advantages for using zebrafish in the study of human
disease and development including the ease and low cost of
raising large numbers of fish and the highly conserved genetic
and biochemical pathways between zebrafish and mammals
[95].
As zebrafish RMS is highly similar to human ERMS,
by using fluorescent transgenic approaches, it is more con-
venient to understand histogenesis and different aspects of
tumorigenesis in RMS. A robust zebrafish model of RAS-
induced RMS has been established, sharing twomorphologic
and immunophenotypic features resembling ERMS [51]. In
one case, both are associated with tissue-restricted gene
expression in RMS, while, in another, both comprise a RAS-
induced gene signature. Cross-species microarray compar-
isons confirm that conserved genetic tumor-specific and
tissue-restricted pathways such as RAS and p53 pathways
drive RMS growth. Tg(hsp70-HRASG12V) zebrafish embryos
were generated to evaluate gene expression that mimics RAS
pathway activation during tumorigenesis to defineRAS target
genes [52]. Another KRASG12D-induced zebrafish embryonal
RMS was utilized to assess the therapeutic effects. By the
blockage of two major downstream signaling pathways,
MAPK/ERK and AKT/S6K1, the model showed that inhibi-
tion of translation initiation suppresses tumor cell prolifera-
tion [52].
All the above zebrafish cancer models share similar cellu-
lar features and molecular pathways with human RMS, espe-
cially ERMS, and can demonstrate a response to therapies
in a similar manner with human RMS. Thus, a tremendous
opportunity is available to implement these animal models
into different steps for novel targeted therapeutic develop-
ment.
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6.3. Mouse Models in RMS. Mouse models established from
in vivo studies may contribute to the understanding of the
genetic basis in tumor development and progression andmay
help to test the efficacies of novel antineoplastic agents.
The importance of PAX3/PAX7-FKHR fusion proteins in
the progression of ARMS tumorigenesis is evident from both
in vitro and in vivo studies. Transgenic mouse models gener-
ated with the PAX-FKHR fusion genemimic the formation of
human ARMS [67]. A mouse model was developed with het-
erozygous loss of Sufu, a tumor suppressor inHedgehog (Hh)
signaling, combined with p53 loss driven ERMS with a low
penetrance (9%) [53]. These studies indicate that the models
consistently formingARMSnot only need the introduction of
the PAX-FKHR fusion gene but also need to be accompanied
by other genetic events, such as p53 pathway disruption [54].
Compared with ARMS, ERMS models are more complex
to generate because of their lower tumor penetrance and
longer latency. JW41 cells from the p53/c-fos double mutant
mice models resemble human ERMS cells morphologically
and express similar characteristic markers [55]. The overex-
pression of the Wnt2 gene identified in JW41 cells confirmed
in human RMS cell lines can allow for further analysis of the
Wnt signaling pathway. Both of these results indicate that the
downregulation of theWnt pathway contributes to resistance
to apoptosis and the inhibition of myogenic differentiation in
ERMS.
Using Ptch1, p53, and/or Rb1 conditional mouse models
and controlling prenatal or postnatal myogenic cell of origin,
Rubin et al. demonstrated that the loss of p53 in maturing
myoblasts related to tumorigenesis of ERMS [96]. They also
indicated that Rb1 alteration with other oncogenic factors
was strongly associated with an undifferentiated phenotype,
acting as a modifier. In addition, they highlighted a sub-
set of p53-deficient ERMSs arising from Myf6-expressing
myoblasts, which had the same latency with Pax7-expressing
murine satellite cells in the study.
7. Potential Therapeutic Targets in RMS
Detection of genomic imbalances and identification of the
crucial effective genes can contribute to identifying novel
potential biomarkers and relevant targets for clinical therapy
in RMS.
Survivin-responsive conditionally replicating adenovi-
ruses can regulate multiple factors (Surv.m-CRAs) [41].
Although Surv.m-CRA can efficiently replicate and potently
induce cell death in RMS cells, the cytotoxic effects are more
pronounced in RSC-enriched or RSC-purified cells than
in RSC-exiguous or progeny-purified cells. Injections of
Surv.m-CRAs into tumor nodules generated by transplanting
RSC-enriched cells induce significant death in RMS cells and
regression of tumor nodules.The unique therapeutic features
of Surv.m-CRA include not only its therapeutic effectiveness
against RMS but also its increasing effectiveness against CSC,
suggesting that Surv.m-CRA may be a promising anticancer
agent [41].
Rapamycin, an inhibitor of mTOR, can abrogate RMS
tumor growth in a xenograft mouse model [97]. The
tumors in the rapamycin-treatedmice group show significant
reduction of proliferation and invasiveness and induction
of apoptosis. The tumor growth inhibition is simultaneous
associated with the diminution of mTOR and Hh pathways,
which are implicated in the pathogenesis of RMS.The results
indicate that using rapamycin either alone or in combination
with traditional chemotherapeutic drugs may represent a
potential targeted agent for therapeutic intervention. Ampli-
fication and mutational activation of Fibroblast Growth Fac-
tor Receptor 4 (FGFR4) in RMS cells promote tumor pro-
gression [98]. Ponatinib is the most potent FGFR4 inhibitor
to block wild-type RMS cell growth, mutate FGFR4 through
increasing apoptosis, and suppress the FGFR4 downstream
target STAT3. Ponatinib treatment slows tumor growth in
RMS mouse models expressing mutated FGFR4 [98]. Pona-
tinib as an FGFR4 inhibitor shows potential to act as an
effective therapeutic agent for RMS tumors.The expression of
CXC chemokine receptor 4 (CXCR4), CXCR7, and Vascular
Endothelial Growth Factor (VEGF) indicates poor prognosis
in a variety of malignancies, including RMS cell lines. Most
samples in a large series of clinical RMS cases show asso-
ciation with high expression of these antagonists regardless
of their subtypes [99]. However, there are significant corre-
lations with high expression of CXCR4 and VEGF in both
ERMS and ARMS. High VEGF expression is predictive of
adverse prognostic factors in RMS, as the expression of these
angiogenesis factors was compared with clinicopathological
parameters and prognosis. Considering their overexpression
in RMS, these chemokine receptors and VEGF could provide
potential molecular therapeutic targets in RMS. Some ARMS
cell lines have undergone apoptosis in response to antineo-
plastic drugs, such as bortezomib. The proapoptotic BH3
only family member NOXA acts as an upregulated protein
downstream PAX3-FKHR, resulting in increased cell sensi-
tivity to bortezomib. Apoptosis in response to bortezomib
can be reversed by shRNA knockdown of Noxa. PAX3-
FKHR upregulation of Noxa creates a potential therapeutic
insight into inducing apoptosis in ARMS cells.This apoptosis
pathway could represent a specific targeted therapy against
PAX3-FKHR-expressing ARMS cells [100].
Proton pump activation resulting from intracellular acid-
ificationmay be an energetic mechanism to escape apoptosis.
V-ATPase is an ATP-driven proton pump acidifying the
intracellular compartment and transports protons across the
plasma membrane. Esomeprazole as a V-ATPase inhibitor in
the PPI administration interferes with intensive ion trans-
porter activity of RMS cells and induces remarkable cytotoxi-
city. RMS expresses a higher level ofV-ATPase comparedwith
other sarcomas.Therefore, RMS should be very susceptible to
esomeprazole treatment and V-ATPase could be considered
as a promising selective target for treatment [101].
8. Conclusion and Future Prospects
For RMS, the current challenges include how to iden-
tify promising novel therapeutics and integrate them into
existing therapy. For better understanding of congenital
and epigenetic modifications in the development of RMS,
this review summarizes the recent genome-wide studies on
molecular and genetic alterations to decipher the underlying
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tumorigenesis mechanisms. There is a link between genetic
and epigenetic alterations responsible for a variety of tumor
cell growth, proliferation, differentiation, apoptosis, and
therapy-resistance mechanisms. The identification of the
prognostic value of the PAX-FKHR fusion status in RMS
is one of the most important shifts in the lineage and the
risk assessment of RMS, which exerts an oncogenic effect
through multiple pathways and is incorporated into most
relevant studies. The misbalanced expression of a number of
miRs involved in the regulation of myogenic differentiation
also implicates the tumors’ escape suppressive mechanisms.
Moreover, we described several in vivo models of RMS
to explore underlying histogenesis and different aspects of
tumorigenesis. Recent work on CSCs has also contributed
to understanding the cell origins, refining molecular char-
acterization, and elucidating the underlying basis of refrac-
tory responses to current adjuvant treatments of subsets of
tumors.These integrative approaches can provide opportuni-
ties to identify diagnostic and prognostic biomarkers applied
to the individual targeted therapy and significantly improve
RMS prognosis.
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